Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

639 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
snRNAs from Radical Prostatectomy Specimens Have the Potential to Serve as Prognostic Factors for Clinical Recurrence after Biochemical Recurrence in Patients with High-Risk Prostate Cancer.
Mikami H, Noguchi S, Akatsuka J, Hasegawa H, Obayashi K, Takeda H, Endo Y, Toyama Y, Takei H, Kimura G, Kondo Y, Takizawa T. Mikami H, et al. Cancers (Basel). 2024 May 1;16(9):1757. doi: 10.3390/cancers16091757. Cancers (Basel). 2024. PMID: 38730709 Free PMC article.
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
Mikami H, Feng S, Matsuda Y, Ishii S, Naoi S, Azuma Y, Nagano H, Asanuma K, Kayukawa Y, Tsunenari T, Kamikawaji S, Iwabuchi R, Shinozuka J, Yamazaki M, Kuroi H, Ho SSW, Gan SW, Chichili P, Pang CL, Yeo CY, Shimizu S, Hironiwa N, Kinoshita Y, Shimizu Y, Sakamoto A, Muraoka M, Takahashi N, Kawa T, Shiraiwa H, Mimoto F, Kashima K, Kamata-Sakurai M, Ishikawa S, Aburatani H, Kitazawa T, Igawa T. Mikami H, et al. Cancer Immunol Res. 2024 Apr 1:OF1-OF12. doi: 10.1158/2326-6066.CIR-23-0638. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38563577
Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer.
Mikami H, Feng S, Matsuda Y, Ishii S, Naoi S, Azuma Y, Nagano H, Asanuma K, Kayukawa Y, Tsunenari T, Kamikawaji S, Iwabuchi R, Shinozuka J, Yamazaki M, Kuroi H, Ho SSW, Gan SW, Chichili P, Pang CL, Yeo CY, Shimizu S, Hironiwa N, Kinoshita Y, Shimizu Y, Sakamoto A, Muraoka M, Takahashi N, Kawa T, Shiraiwa H, Mimoto F, Kashima K, Kamata-Sakurai M, Ishikawa S, Aburatani H, Kitazawa T, Igawa T. Mikami H, et al. Cancer Immunol Res. 2024 Mar 20. doi: 10.1158/2326-6066.CIR-23-0638. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38558120
Applicable predictive factors extracted from peak flow trajectory for the prediction of asthma exacerbation.
Yang Y, Kimura H, Yokota I, Makita H, Takimoto-Sato M, Matsumoto-Sasaki M, Matsumoto M, Oguma A, Abe Y, Takei N, Goudarzi H, Shimizu K, Suzuki M, Nishimura M, Konno S; Hi-CARAT investigators. Yang Y, et al. Ann Allergy Asthma Immunol. 2024 Apr;132(4):469-476. doi: 10.1016/j.anai.2023.11.015. Epub 2023 Nov 24. Ann Allergy Asthma Immunol. 2024. PMID: 38006971 Clinical Trial.
A case of marked rectal stenosis due to Douglas' pouch metastasis of renal pelvic carcinoma successfully treated with salvage enfortumab vedotin: correlation between serum KL-6 levels and tumor response.
Akatsuka J, Kimura G, Katsu A, Hasegawa H, Mikami H, Yanagi M, Endo Y, Takeda H, Toyama Y, Kondo Y. Akatsuka J, et al. Among authors: mikami h. IJU Case Rep. 2023 Sep 26;6(6):449-453. doi: 10.1002/iju5.12645. eCollection 2023 Nov. IJU Case Rep. 2023. PMID: 37928289 Free PMC article.
639 results